A daily synthesis of the 103 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-14. JSPR +18.90%, BTAI +16.75%, and GALT +16.09% led the upside on no fresh news; XAIR -22.96%, SPRO -22.02%, and NTHI -14.81% led the downside on a reverse-split distribution, a $105M royalty-financing sell-the-news reaction, and insider-distribution flow. The cross-cutting pattern was a zero-clean-catalyst day where 6 of 6 top movers were Class 1/4/5 (mechanical, strategic, prior-cycle) and zero were Class 2 (clean clinical / regulatory readout) — a structurally quiet tape where XBI +0.07% essentially matched SPY +0.36%. Sector leader: Psychedelics & Related +3.09% (n=5).
A daily synthesis of the 140 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-13. Q32 Bio (QTTB) ran +90.72% on positive 36-week topline data from Part B of SIGNAL-AA, a bempikibart Phase 2a in alopecia areata. On the downside, Cadrenal (CVKD -16.26%) sold off despite positive late-breaking Phase 2 HIT data after a 2.94M-share secondary offering by selling stockholders hit the tape the same day; Cue Biopharma (CUE -15.93%) closed a previously announced $50M private placement at $33.21; Aardvark (AARD -21.58%) gave back without fresh news as the market lost patience with the delayed Q2 FDA guidance on its ARD-101 clinical hold. The cross-cutting pattern was biotech-specific risk-off on dilution and missing-Q2 guidance, with XBI -2.32% lagging XLV +0.35% by 267bps. Sector leader: Generic Drugs +3.02% (n=5).
A daily synthesis of the 101 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-10. Aardvark rebounded +52.00% on 11.14x volume, Forte added +19.67% as the FB102 vitiligo readout continued to reprice, and Rapid Micro Biosystems gained +17.82% on life-sciences tools follow-through. On the downside, Profusa fell -16.54% in a post-split resale-registration cycle, Anbio Biotechnology lost -15.78% after a mixed shelf filing, and Tvardi gave back -13.68% after its early-week TTI-109 Phase 1 rally. The cross-cutting pattern was a biotech-specific risk-off tape: SPY rose +0.43%, but XBI fell -3.20%, IBB fell -2.68%, and XLV fell -0.82%.
A daily synthesis of the 97 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-09. Forte Biosciences surged +78.33% on 8.38x volume after reporting positive Phase 1b FB102 vitiligo data (29.6% mean FVASI improvement at week 24, p=0.020); TransCode Therapeutics ran +21.84% on a Nasdaq listing-conversion catalyst (Series A/B preferred-to-common); Oncolytics Biotech gained +16.12% on a delayed reaction to the July 8 auditor-change disclosure (E&Y → Baker Tilly, with going-concern explanatory paragraph from prior reports). On the downside, Ionis Pharmaceuticals fell -23.90% on 7.51x volume after the CARDIO-TTRansform Phase 3 trial for eplontersen in ATTR-CM missed its primary efficacy endpoint; Tvardi Therapeutics gave back -24.00% as the post-Phase-1 TTI-109 readout profit-taking continued; TScan Therapeutics fell -15.87% on fading Phase 3 alignment momentum. The session was a clean broad-sector rally: the S&P 500 closed +0.85%, the XBI +0.80%, the IBB +0.69%, the XLV +0.94% — broad healthcare outperformed the S&P 500 and the 5.43% StDev was the signature of marquee single-stock flow (FBRX, IONS) on an otherwise positive tape. Sector leaders: Psychedelics +3.57% (n=5), Diagnostics +2.89% (n=31), Genetics & Genomics +2.87% (n=7). Sector laggards: New England -2.61% (n=7), Stem Cells / Cellular Therapy -0.93% (n=24).
A daily synthesis of the 120 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-08. Tvardi's positive Phase 1 TTI-109 STAT3-inhibitor data extended Tuesday's run (TVRD +61.29% on 8.94x volume, 5d +163.2%); Elicio bounced +24.64% after closing a $15M registered stock sale to fund its KRAS cancer program; TScan Therapeutics ran +17.76% on Phase 3 alignment. On the downside, BioXcel Therapeutics fell -22.87% on 4.99x volume as the market priced in financing risk ahead of IGALMI's at-home sNDA action date (Nov 14, 2026); Context Therapeutics' onapristone extended-release data in ovarian cancer disappointed (CNTX -14.91%); Profusa gave back -14.59% as the post-split squeeze from Monday continued to fade. The session was a clean broad-sector fade: the S&P 500 closed -0.31%, the XBI -0.55%, the IBB -0.95%, the XLV -1.30% — broad healthcare underperformed the broad market for the first session in three days. Sector leaders: Psychedelics +3.24% (n=5), Genetics & Genomics +1.63% (n=7). Sector laggards: AI / Machine Learning -3.39% (n=6), Devices — Implants -3.16% (n=10).
A daily synthesis of the 142 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-07. Vertex announced an all-cash $10B acquisition of Crinetics at $85/share, lifting CRNX +98.74% to a 52-week high; Tvardi's positive Phase 1 TTI-109 STAT3-inhibitor data sent TVRD +54.23% on 24x volume; Akari +42.02% on a LoRusso SAB appointment. On the downside, CollPlant called a July 29 EGM to vote on a 16.7x share-capital increase, Elicio was hit with a Pomerantz securities-fraud probe, and CapsoVision extended a multi-week slide with no fresh catalyst. The session was a clean Class-2-and-3 day: a marquee buyout, a clinical readout, a credibility hire, and a financing overhang — not mechanical.
A daily synthesis of the 110 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-06. Celularity ran +29.09% on a sub-$1 short-squeeze; Profusa jumped +21.93% on the eve of a 1-for-25 reverse split; BioXcel cratered -20.29% on the slide toward Nasdaq bid-price compliance; Aktis Oncology fell -16.37% as the radiopharm sector pulled back -5.10%. No clean single-day catalysts in the top six — all six are continuation plays or mechanical events.
A daily synthesis of the 125 anomaly-flagged stock moves across the ~600 public biotech and life-sciences companies we track. Markets were closed Friday, July 3 for the observed Independence Day holiday; all prices reflect Thursday, July 2 close. Elicio down 37% on Phase 2 miss plus offering; PPCB up 23% on $5M buyback; reverse splits punished PFSA and CRIS. RNA/Gene Therapy sector led with +3.55% average move.
A daily synthesis of the 125 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-02 (post-market). Elicio cratered -37.35% on a Phase 2 miss in pancreatic cancer; Profusa announced a 1-for-25 reverse split; Propanc surged +22.92% on a $5M buyback. RNA/Gene Therapy and Small-Molecule Pharma led sector averages (+3.55% and +2.23%); Devices — Imaging and Diagnostics lagged (-2.28% and -0.38%). XBI +2.50%, IBB +2.93%, XLV +2.63% — healthcare broadly bid with a sharp divergence underneath.
A daily synthesis of the 143 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-01. Neuphoria cratered -18.76% on 6.84x volume after Merck terminated its partnered Alzheimer's Phase 2. Devices and Diagnostics led sector averages (+2.48% and +2.35%); small-molecule pharma, RNA/gene therapy, and psychedelics lagged. Only one of the top six movers had a clean single-name catalyst on the day — most of the tape was continuation of prior-cycle news.
Deep analysis of the FDA's June 29, 2026 announcement of seven companies selected for the PreCheck Pilot Program — what the selection criteria actually were, who the winners are, what their facility investments look like, and what this means for each company's strategic positioning, the broader CDMO landscape, and the US biopharma supply chain.
Across our internal biotech cohort, 71 publicly-verified upcoming catalyst events sit in the database — 17 with exact PDUFA/readout dates, 51 in sponsor-stated quarters, and 3 still TBD. Today's breakdown covers Q3 2026 (17), Q4 2026 (18), and H1 2027 (12), plus the cross-cutting conference placements, the 41 H1-2026 items we deliberately crossed off the calendar, and one notable caveat (an outlook-therapeutics 4th BLA resubmission) that explains why some 'exact date' PDUFAs are actually long-shot recoveries.
A daily synthesis of the 154 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-06-26 (post-market, Friday). Curis up 55.98% on 178x volume. Tvardi down 36.44% on 33x volume. Sector rotation into devices, psychedelics, and implants. 154 names moved |%|>= 5%. The full report is at the bottom.
A daily synthesis of the 105 anomaly-flagged stock moves across the ~600 public biotech and life-sciences companies we track. Today's signal: AI-designed and psychedelic-adjacent drug-discovery platforms are being rewarded on clinical validation (ABSI +34.75%, DFTX +18.23%), while orphan-disease single-asset micro-caps are being punished on dilution (CGTX -34.33%, NUWE -33.52%). Includes a 6-class taxonomy of mover signal and the underlying catalysts for the top 6 movers.
No articles in this category match your search or filters.